Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Cars.com
CARS
5
LIFE HEALTHCARE GROUP HOLDINGS UNSPON ADR EA REPR 4 ORD ZAR0.00
LTGHY
US Stock MarketDetailed Quotes
AMRN Amarin
- 0.4026
- -0.0200-4.73%
Close Apr 4 16:00 ET
- 0.4000
- -0.0026-0.65%
Post 20:01 ET
166.75MMarket Cap-2.01P/E (TTM)
0.4212High0.3900Low2.56MVolume0.4190Open0.4226Pre Close1.03MTurnover0.68%Turnover RatioLossP/E (Static)414.19MShares1.110052wk High0.34P/B152.08MFloat Cap0.354052wk Low--Dividend TTM377.75MShs Float675.0000Historical High--Div YieldTTM7.38%Amplitude0.3540Historical Low0.4010Avg Price1Lot Size
About Amarin Company
Amarin Corp. Plc is a pharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. It focuses on the development and commercialization of Vascepa capsules. The company was founded by Geoffrey William Guy on March 1, 1989 and is headquartered in Dublin, Ireland.
Company Profile
SymbolAMRN
Company NameAmarin
Listing DateApr 1, 1993
Issue Price6.00
Founded1989
CEOMr. Aaron D. Berg
MarketNASDAQ
Employees275
Securities TypeDR
ADS Ratio1.0 : 1.0
Fiscal Year Ends12-31
AddressOne Central Plaza,36 Dame Street,5th Floor
CityDublin
ProvinceDublin
CountryIreland
Zip Code2
Phone353-1-6699-020
Websitehttp://www.amarincorp.com
Company Executives
- Name
- Position
- Salary
- Aaron D. Berg
- Director, President and Chief Executive Officer
- 2.45M
- Jonathan N. Provoost
- Executive Vice President, Chief Legal and Compliance Officer and Secretary
- 659.26K
- Dr. Steven B. Ketchum, PhD
- Executive Vice President, President, Research and Development and Chief Scientific Officer
- 2.35M
- Peter Fishman
- Senior Vice President, Chief Financial Officer and Principal Accounting Officer
- --
- Dr. Odysseas D. Kostas, M.D.
- Chairman of the Board
- 650.41K
- Patrice Bonfiglio
- Independent Director
- 626.87K
- Diane E. Sullivan
- Independent Director
- 630.83K
- Oliver O'Connor
- Independent Director
- 611.85K
- Louis Sterling, III
- Independent Director
- 629.35K
- Keith L. Horn
- Independent Director
- 632.09K
- Dr. Paul Cohen, M.D.
- Independent Director
- 622.06K
- Mark DiPaolo, Esq.
- Independent Director
- 621.00K
Market Insights
Discussing
Chinese stock earnings surge: Will profit sustain the rally?
1. Which sectors are likely to be market highlights this season? 2. With the government's emphasis on technological innovation and sustaina
Moomoo News Global
Mar 4 23:26
China's Two Sessions: Key Takeaways on Stock Price Movements Before and After the Meetings
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
Unlock Now
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Unlock Now